Key result
PCSK9 targeting emerges as a promising therapeutic strategy for hypercholesterolemia.
Why the study?
Do PCSK9 inhibitors improve the management of hypercholesterolemia?
Do PCSK9 inhibitors improve the management of hypercholesterolemia?
Targeting PCSK9 is highlighted as a promising approach for the management of hypercholesterolemia.
*Corresponding author: Constantine E. Kosmas, MD, PhD, 168-24 Powells Cove Blvd., Beechhurst, NY 11357. E-mail: cekosmas1@gmail.com Citation: Kosmas CE, Morcelo R, Martinez I, Peña Polanco V, Hilario E, Hernandez N, Montan PD, and Guzman E (2017) Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): A New Promising Approach for the Management of Hypercholesterolemia. Enliven: Clin Cardiol Res 4(e1): 001.
No takes yet. Share an insight, caveat, or question.
Constantine et al. (2018) conducted an editorial in Hypercholesterolemia. Targeting PCSK9 was evaluated. Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is discussed as a promising new approach for the management of hypercholesterolemia.
Synapse has enriched 4 related papers. Consider them for comparative context: